MyFinsight
Home
Blog
About
Contact
Net decrease in cash
and cash...
-$38,114K
Equity-based compensation
$1,318K
Prepaid expenses and
other current assets
-$1,166K
Accrued expenses and
other current...
$434K
Non-cash lease expense
-$153K
Depreciation and
amortization
$73K
Net cash used in
operating activities
-$21,584K
Net cash used in
investing activities
-$15,847K
Net cash used in
financing activities
-$460K
Effect of foreign
exchange rate changes on...
-$223K
Canceled cashflow
$3,144K
Net loss
-$22,687K
Purchases of
available-for-sale debt securities
$15,735K
Purchases of property and
equipment
$112K
Payment of offering
costs
$414K
Principal payments on
finance lease
$46K
Other non-current
assets
$1,016K
Accretion of discount on
available-for-sale debt securities
$816K
Operating lease
liabilities
-$157K
Accounts payable
-$52K
Back
Back
Cash Flow
Hemab Therapeutics Holdings, Inc. (COAG)
Hemab Therapeutics Holdings, Inc. (COAG)
source: myfinsight.com